ASAM supports a wide variety of measures to prevent and research substance-related problems.

Other Addiction Policy Areas

ASAM is committed to increasing access to and improving the quality of evidence-based addiction prevention services. ASAM supports a wide variety of measures to prevent substance-related problems, understanding that carefully planned prevention measures can reduce the initiation of substance use. Additionally, ASAM advocates for a robust research agenda informed by patient experience and clinical needs. Specific research priorities include effective prevention programs and pharmacological and non-pharmacological treatments for addiction and improved medical treatments for stimulant use disorder.

Advocacy Action

  • Advocacy News February 26, 2021

    ASAM Issues Public Policy Statement on Advancing Racial Justice in Addiction Medicine

    On February 25th, the American Society of Addiction Medicine (ASAM) issued a Public Policy Statement on Advancing Racial Justice in Addiction Medicine , the first in a series of statements on addressing the systemic racism that permeates drug policy and impacts both the development of addiction as well as access to treatment for millions of Americans with substance use disorder (SUD). Recognizing systemic racism as a social determinant of health, the public policy statement released today is part of ASAM’s effort to recognize, understand, and counteract the effects of America’s historical, pervasive, and continuing systemic racism as it relates to addiction prevention, early intervention, diagnosis, treatment, and recovery.
    Full story
  • Advocacy News January 8, 2021

    ASAM Releases Its 2020 Advocacy Year in Review

    ASAM released its 2020 Advocacy Year in Review, which provides an overview of some of the new policies and resources that ASAM and its State Chapters helped advance in 2020, by working closely with federal and state policy-makers and other key stakeholders.
    Full story

National Initiatives

S. 2032 - Cannabidiol and Marijuana Research Expansion Act

ASAM supports the Cannabidiol and Marijuana Research Expansion Act, which would work to ensure that research on CBD and other potentially beneficial marijuana-derived substances is based on sound science while simultaneously reducing the regulatory barriers associated with conducting research on marijuana. Read more

H.R.3797 - Medical Marijuana Research Act of 2019

ASAM endorsed the Medical Marijuana Research Act, which would create an exception for marijuana from the current obstacles of Schedule I registration and review procedures. This would empower researchers to more easily research marijuana and understand its effects. Read more

H.R. 7286 - Quit Because of COVID-19 Act

ASAM endorsed the Quit Because of COVID-19 Act which would ensure that all Medicaid and Children's Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.  Specifically, the bill would extend comprehensive tobacco cessation to all Medicaid and CHIP beneficiaries, eliminate cost sharing and prior authorization requirements, and would provide enhanced federal funding to cover the full cost of state outreach campaigns to education providers and Medicaid and CHIP beneficiaries about the benefit.

Subscribe to the ASAM Advocate

Your source for timely, useful news briefings of top stories in addiction policy.